bluebird bio Stock News

These biotechs could crush the market, but there is more to the story.

This company has had a solid year, but there is still plenty of work ahead.

bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.

Sometimes, the financial markets can be highly unpredictable. Reportedly, the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold on Bluebird Bio's (NASDAQ: BLUE ) studies of a s

bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.

The company looks set to continue its good momentum in the early part of next year.

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

bluebird bio has received approval for their first products and are on track to treat their first patient later this year. They have yet to bring in revenues and hold significant amount of debt. They

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

These two companies have performed almost equally poorly on the stock market in the past year.

The near term looks good, but the long term might not.

Bluebird Bio has received a lot of attention for pricing two FDA-approved gene therapies at around $3 million annually, but its financial future remains uncertain.

This biotech has made tremendous progress recently.

This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.